Association between prophylactic indomethacin and death or bronchopulmonary dysplasia: A systematic review and meta-analysis of observational studies

Seminars in Perinatology

Volumn 42, Issue 4, 2018, Pages 228-234

  Jensen, Erik A ^a   Foglia, Elizabeth E ^a   Schmidt, Barbara ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Bronchopulmonary dysplasia; Meta analysis; Patent ductus arteriosus; Premature infant; Prophylactic indomethacin

Indexed keywords

INDOMETACIN; OXYGEN; NONSTEROID ANTIINFLAMMATORY AGENT;

BRAIN HEMORRHAGE; DATA ANALYSIS; HUMAN; INFANT MORTALITY; LUNG DYSPLASIA; MEDICAL RESEARCH; META ANALYSIS; OBSERVATIONAL STUDY; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SURVIVOR; SYSTEMATIC REVIEW; AGE; MORTALITY; NEWBORN; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHOPULMONARY DYSPLASIA; DUCTUS ARTERIOSUS, PATENT; HUMANS; INDOMETHACIN; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; OBSERVATIONAL STUDIES AS TOPIC; TREATMENT OUTCOME;

EID: 85048314153     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2018.05.005     Document Type: Review

References (20)

1. Elliott, R., Starling, M., Neutze, J., Medical manipulation of the ductus arteriosus. Lancet 1:7899 (1975), 140–142.
2. Friedman, W., Hirschklau, M., Printz, M., Pitlick, P., Kirkpatrick, S., Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 295:10 (1976), 526–529.
3. Heymann, M., Rudolph, A., Silverman, N., Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 295:10 (1976), 530–533.
4. Fowlie, P.W., Davis, P.G., McGuire, W., Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev(7), 2010 CD000174.
5. Marshall, D.D., Kotelchuck, M., Young, T.E., et al. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. Pediatrics 104:6 (1999), 1345–1350.
6. Oh, W., Poindexter, B.B., Perritt, R., et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 147:6 (2005), 786–790.
7. Palta, M., Gabbert, D., Weinstein, M.R., Peters, M.E., Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. The Newborn Lung Project. J Pediatr 119:2 (1991), 285–292.
8. Schmidt, B., Davis, P., Moddemann, D., et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 344:26 (2001), 1966–1972.
9. Stoll, B.J., Hansen, N.I., Bell, E.F., et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. J Am Med Assoc 314:10 (2015), 1039–1051.
10. Horbar, J.D., Edwards, E.M., Greenberg, L.T., et al. Variation in performance of neonatal intensive care units in the United States. JAMA Pediatr, 171(3), 2017, e164396.
11. Rolnitsky, A., Lee, S., Piedbouf, B., Harrison, A., Shah, P., Network., C.N., Prophylactic interventions in neonatology: how do they fare in real life?. Am J Perinatol 32:12 (2015), 1098–1104.
12. Jensen, E.A., Dysart, K.C., Gantz, M.G., et al. Association between use of prophylactic indomethacin and the risk for bronchopulmonary dysplasia in extremely preterm infants. J Pediatr 186 (2017), 34–40 e2.
13. Nelin, T., Pena, E., Giacomazzi, T., et al. Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU. J Perinatol 37:8 (2017), 932–937.
14. Cordero, L., Nankervis, C., Delooze, D., Giannone, P., Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants?. J Perinatol 27:3 (2007), 158–163.
15. Laughon, M., Bose, C., Clark, R., Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes. J Perinatol 27:3 (2007), 164–170.
16. Gudmundsdottir, A., Johansson, S., Håkansson, S., Norman, M., Källen, K., Bonamy, A., Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. Neonatology 107:2 (2015), 87–92.
17. Mondal, T., Chaudhuri, D., Li, B., Shivananda, S., Dutta, S., Prophylactic indomethacin worsens short-term respiratory outcomes in extremely low-birth-weight infants. Am J Perinatol 31:1 (2014), 61–67.
18. Liebowitz, M., Clyman, R., Prophylactic indomethacin compared with delayed conservative management of the patent ductus arteriosus in extremely preterm infants: effects on neonatal outcomes. J Pediatr 187 (2017), 119–126.
19. Madan, J.C., Kendrick, D., Hagadorn, J.I., Frantz, I.D., National Institute of Child Health and Human Development Neonatal Research Network. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics 123:2 (2009), 674–681.
20. Reese, J., Shelton, E., Slaughter, J., McNamara, P., Prophylactic indomethacin revisited. J Pediatr 186 (2017), 11–14 e1.